An active MMP‐8 (aMMP‐8) point‐of‐care (PoC) test, has been validated across countries in both the adolescent and adult populations as a tool to define active and inactive sites of periodontal disease, evaluate prognosis, and assess patients during the treatment and maintenance phases (Alassiri et al., 2018; Heikkinen et al., 2016; Izadi Borujeni et al., 2015; Johnson et al., 2016; Lähteenmäki et al., 2020; Leppilahti et al., 2018; Lorenz et al., 2017; Nwhator et al., 2014; Räisänen et al., 2018, 2019; Sorsa et al., 2020, Sorsa, Grigoriadis et al., 2021). The gene discussed is MMP8; the disease is periodontal disorder.